
## Eduardo Seclen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/70806/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes. Molecular Therapy - Methods and Clinical Development, 2021, 23, 198-209.	4.1	18
2	Prospects of CRISPR/Cas9 for HIV Elimination. AIDS Reviews, 2019, 21, 109-111.	1.0	1
3	Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR–Cas9 genome-editing efficiency. Nature Biotechnology, 2018, 36, 95-102.	17.5	206
4	330. Using CRISPR/Cas9 to Edit Hematopoietic Stem and Progenitor Cells. Molecular Therapy, 2016, 24, S132.	8.2	0
5	Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology, 2015, 12, 67.	2.0	7
6	Bone marrow transplant to fight cancer and HIV infection. AIDS Reviews, 2014, 16, 53-4.	1.0	0
7	Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor. Antiviral Therapy, 2012, 17, 921-926.	1.0	44
8	High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement. Journal of Clinical Microbiology, 2011, 49, 3380-3382.	3.9	18
9	Short Communication: Severe Immune Suppression in Patients Infected with R5-Tropic HIV-1 Strains Is Associated with Increased gp120 Net Charge at Variable Regions. AIDS Research and Human Retroviruses, 2011, 27, 965-967.	1.1	9
10	Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy. Journal of Infectious Diseases, 2011, 204, 139-144.	4.0	32
11	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. Aids, 2010, 24, 467-469.	2.2	34
12	Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. Journal of Antimicrobial Chemotherapy, 2010, 65, 1493-1496.	3.0	40
13	Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 2502-2504.	3.0	19
14	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists–authors' response. Journal of Antimicrobial Chemotherapy, 2010, 65, 2057-2058.	3.0	0
15	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. Journal of Antimicrobial Chemotherapy, 2010, 65, 1486-1492.	3.0	63
16	Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. Aids, 2010, 24, 777-779.	2.2	11
17	Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. Journal of Antimicrobial Chemotherapy, 2009, 63, 1006-1010.	3.0	64
18	HLA Genes in Mayos Population from Northeast Mexico. Current Genomics, 2007, 8, 466-475.	1.6	18